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Abstract
Background: Circulating plasma Epstein Barr Virus DNA (EBV-DNA) is a sensitive and specific
marker of nasopharyngeal carcinoma (NPC). The mainstay of treatment of metastatic NPC is
systemic chemotherapy and resection for solitary metastasis. Despite high response rate to
chemotherapy, complete remission is uncommonly seen.
Case Presentation: We report a case of recurrent metastatic NPC in a 43-year-old man, who
achieved complete remission three times with chemotherapy and surgery. Serial plasma EBV-DNA
levels were measured during the course of disease. The patient had three episodes of recurrences
of NPC manifested as distant metastasis. Both time, rise in the plasma EBV-DNA level preceded
detection of recurrences by imaging. Following systemic chemotherapy, he achieved complete
remission each time, of which was confirmed by 18-flourodeoxyglucose positron emission
tomography and hepatectomy pathology. The plasma EBV-DNA level dropped to zero copy/ml at
the time of each remission.
Conclusion:  This case highlights the high chemosensitivity of NPC by illustrating a rare
occurrence of complete response of metastatic NPC to chemotherapy. This case also underscores
the usefulness of EBV-DNA as a useful tool in monitoring NPC by its ability to detect early
recurrence and excellent correlation with treatment response.
Background
The recent development in nucleic acids in serum and
plasma has opened up many new areas in molecular diag-
nosis. In the field of oncology, circulating plasma/serum
Epstein Barr Virus (EBV) DNA in nasopharyngeal carci-
noma (NPC) is a good example. The real-time polymerase
chain reaction (RT-PCR) is a reliable and reproducible
technique, which allows a rapid quantification of plasma
EBV DNA, thus rendering it an attractive tool in the mon-
itoring of treatment response [1,2]. The test is highly sen-
sitive because it targets the BamHI-W repeat region of the
EBV genome [2]. This test became available for clinical use
at our oncology centre in 2002. Though it is uncommon
to see patients with metastatic NPC achieve partial
response to chemotherapy, it is very rare to observe com-
plete response. Here we report a case which illustrates rare
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occurrence of complete response to chemotherapy and
highlights good correlation between plasma EBV DNA
and FDG-PET scan and pathology. Written consent was
obtained from the patient for publication of this report.
Case Presentation
A 43-year old man was referred to our cancer center in
October, 2001 with stage IIb undifferentiated nasopha-
ryngeal carcinoma (T2N1M0). He completed radical radi-
otherapy in December, 2001, and achieved complete
remission afterwards. Although baseline plasma EBV
DNA was not available, patient had undetectable plasma
EBV DNA which was measured within one week after radi-
otherapy.
Upon a routine follow-up in August, 2002, the patient
developed with an asymptomatic rise in the plasma EBV
DNA level at 129,437 copies/ml. A subsequent FDG-pos-
itron emission and computered tomography fusion scan
(FDG-PET-CT) showed a 4 cm hypermetabolic solitary
metastasis in the right lobe of liver with a FDG standard
uptake value (SUV) of 7.6 (Figure 1). Following treatment
with six courses of paclitaxel and carboplatin chemother-
apy, his plasma EBV DNA level fell to undetectable level,
and a subsequent PET-CT performed immediately after
completion of chemotherapy confirmed a reduction in
the size and SUV of the liver metastasis (Figure 1). A right
hepatectomy was performed at two weeks after the end of
chemotherapy, and pathological examination of the
resected specimen showed necrotic tissues without any
evidence of viable malignant cells.
The patient enjoyed a disease-free period of about nine
months until a second disease relapse in September,
2003, when he was found to have asymptomatic rise in
plasma EBV-DNA level to 678 copies/ml. A subsequent
PET-CT confirmed multiple hyper-metabolic recurrences
in the liver, lung and pancreatic head (Figure 2). After 2
courses of second-line chemotherapy with gemcitabine
and carboplatin, his plasma EBV DNA level fell to unde-
tectable level which coincided with complete disappear-
ance of metastatic lesions (i.e. complete remission) on
PET-CT in October, 03 (Figure 2). He completed a total of
4 cycles of gemcitabine and carboplatin and remained dis-
ease-free until 4 months later in February 2004, when he
developed a third relapse which was heralded by an
asymptomatic and progressive rise in plasma EBV-DNA
levels from 56 to 329 copies/ml over a 2 month period. A
PET-CT performed in April 2004 confirmed recurrence in
the liver and pancreatic head. He was re-treated with 6
cycles of gemcitabine and carboplatin chemotherapy, and
again, his plasma EBV-DNA level became undetectable
and PET/CT showed complete remission. Upon his last
follow-up in November 2004, he remained disease-free
for 7 months following the last chemotherapy treatment
in 2004.
Conclusion
In our patient, rising levels of plasma EBV DNA was con-
sistently associated with evidence of distant recurrence as
indicated objectively on PET-CT imaging (Figure 3 &
Table 1), before the development of any clinical signs or
symptoms of relapse. Second, radiological evidence of
complete response (delineated by FDG-PET) to chemo-
therapy also coincided consistently with undetectable lev-
els of plasma EBV DNA. We did not perform histological
confirmation of PET-CT detected disease recurrence
because the location and SUV intensity of those abnor-
malities were unlikely due to false-positive or inflamma-
tory causes. Furthermore, studies have shown that PET is
sensitive and specific in detecting recurrent nasopharyn-
geal carcinoma [3,4].
It is observed that patient subsequently developed recur-
rences though plasma EBV DNA dropped to zero copy/ml
when he was having a relatively inactive disease (which is
manifested as clinical and radiological remission). This is
unlikely due to suboptimal EBV DNA assay because the
assay used by our centre is well validated as reported pre-
viously [1,2,5]. It is noteworthy that although plasma EBV
DNA is a sensitive tool in monitoring disease and tumor
burden, zero copy/ml of EBV DNA does not necessarily
equate complete eradication of disease, and close moni-
toring of clinical condition and EBV DNA level are still
required. The case study also points to the importance of
a well standardized and highly sensitive PCR method,
because the relatively low level of EBV DNA detected in
second and third relapse might be missed with a less sen-
sitive PCR method [1,10].
Cell-free EBV DNA was first demonstrated in circulation
of NPC patient by PCR amplification in 1998 [6].
Dependent on number of PCR cycles, modalities of PCR
and various preparations of specimen, different assays of
various sensitivity and specificity were subsequently
developed for detection of circulating EBV DNA [1,7-10].
Several characteristics have enabled circulating EBV DNA
to be widely used in clinical practice for management of
NPC. In our institute, with the use of real time PCR, EBV
DNA in plasma had been demonstrated to be a both sen-
sitive (96%) and specific (93%) marker of NPC [1]. EBV
DNA is undetectable in healthy individuals and those dis-
ease-free patients with history of NPC, while it is raised in
plasma of most patients with active disease. Also, plasma
EBV DNA has a role in staging and prognostication
[11,12]: higher level of EBV DNA is detected in patient
with more advanced UICC stage, and those patients with
non-metastatic NPC have poorer prognosis when there is
persistent high EBV DNA level after radical radiotherapyBMC Cancer 2006, 6:259 http://www.biomedcentral.com/1471-2407/6/259
Page 3 of 5
(page number not for citation purposes)
to nasopharynx. More importantly, detection of EBV DNA
can be used for monitoring of NPC patients for any recur-
rence or metastasis [2,13]. It had been reported by that
rise in EBV DNA might predate clinical relapse up to few
months hence rendering earlier work-up and treatment
feasible [13]. Other potential use of circulating EBV DNA
remains to be elucidated. For example, the use of EBV
DNA in screening general population for NPC is still
under active research. There are also ongoing studies
addressing the improved accuracy of detecting NPC with
combined use of circulating EBV DNA and other serolog-
ical markers. In our centre, we have already completed a
prospective study looking into correlation between
plasma EBV DNA and PET-CT imaging before and after
radiotherapy in patients with advanced NPC. With this
case, apart from reporting an uncommon occurrence of
chemotherapy induced complete remission of metastatic
nasopharyngeal carcinoma, we hope this case can high-
light the good correlation between circulating EBV DNA
and FDG-PET scan in disease monitoring of nasopharyn-
geal carcinoma.
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
SLC Patient care, Concept & design, Preparation of manu-
script
EPH Patient care, Critical revision
SFL Patient care, Critical revision
ATCC Patient care, Critical revision
BBYM Patient Care, Concept & design, Final revision
All authors read and approved the final manuscript
Acknowledgements
Written consent was obtained from the patient for publication of this 
report.
The authors are indebted to the patient for providing informed consent and 
giving kind permission of this report.
A solitary hepatic metastasis (SUV 7.6) was demonstrated by FDG-PET scan (above) Figure 1
A solitary hepatic metastasis (SUV 7.6) was demonstrated by FDG-PET scan (above). After 6 courses of paclitaxel and carbopl-
atin chemotherapy, follow-up scan showed there was resolution of the liver metastasis (below).BMC Cancer 2006, 6:259 http://www.biomedcentral.com/1471-2407/6/259
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Another set of FDG-PET scan showing complete remission following 6 courses of gemcitabine and carboplatin chemotherapy:  hepatic and pancreatic metastases disappeared in Oct, 03 after chemotherapy (above), compared with hypermetabolic lesions  in September, 03 (below) Figure 2
Another set of FDG-PET scan showing complete remission following 6 courses of gemcitabine and carboplatin chemotherapy: 
hepatic and pancreatic metastases disappeared in Oct, 03 after chemotherapy (above), compared with hypermetabolic lesions 
in September, 03 (below).
Each complete remission (CR) coincided with dropping of EBV-DNA level to zero copy/ml, and recurrence of disease was  associated with rise in plasma EBV-DNA level Figure 3
Each complete remission (CR) coincided with dropping of EBV-DNA level to zero copy/ml, and recurrence of disease was 
associated with rise in plasma EBV-DNA level.Publish with BioMed Central    and   every 
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Table 1: the correlation between plasma EBV-DNA level and 
clinical status; clinical and radiological remission is associated 
with falling level of EBV-DNA level to zero copy/ml.
Time EBV DNA copies/ml Clinical Status
Aug, 02 129837 1st relapse
Dec, 02 0 2nd remission
Sept, 02 678 2nd relapse
Nov, 03 0 3rd remission
Feb, 04 56 3rd relapse
April, 04 329
Nov, 04 0 4th remission